Loading clinical trials...
Loading clinical trials...
Multicenter Study for Evaluation of Efficacy and Safety of Perennial Specific Immunotherapy With a Depot House Dust Mite Allergen Extract (D. Pteronyssinus 100%) in Patients With House Dust Mite Sensitivity
The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis
Age
18 - 55 years
Sex
ALL
Healthy Volunteers
No
Allergopharma GmbH & Co. KG
Reinbek, Germany
Start Date
September 1, 2002
Primary Completion Date
February 1, 2005
Completion Date
February 1, 2006
Last Updated
February 11, 2013
House dust mite Novo Helisen Depot
BIOLOGICAL
Lead Sponsor
Allergopharma GmbH & Co. KG
NCT06920771
NCT04874714
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions